What’s the Best Treatment for Enlarged Prostate?

Benign prostatic hyperplasia (BPH), commonly referred to as prostate enlargement, is a noncancerous condition that affects the majority of men as they age—particularly those over 50. While BPH is not associated with an increased risk of prostate cancer, its progressive growth can compress the urethra and lead to bothersome lower urinary tract symptoms (LUTS), including urinary frequency, nocturia, weak stream, hesitancy, urgency, and incomplete bladder emptying.

Treatment selection for BPH is individualized and depends on symptom severity, impact on quality of life, prostate size, urinary flow rate, post-void residual urine volume, and the presence of complications such as recurrent urinary tract infections, bladder stones, hematuria, or acute urinary retention. The American Urological Association (AUA) and European Association of Urology (EAU) guidelines emphasize a stepwise approach: starting with watchful waiting or lifestyle modifications for mild symptoms; progressing to pharmacotherapy for moderate to severe cases; and reserving surgical or minimally invasive therapies for patients with treatment failure, complications, or significant anatomical obstruction.

First-line medical therapy typically includes alpha-1 adrenergic blockers (e.g., tamsulosin, alfuzosin), which relax smooth muscle in the prostate and bladder neck to improve urinary flow and reduce obstructive symptoms. For men with larger prostates (>30–40 mL) or elevated prostate-specific antigen (PSA) levels, 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) may be added—or used alone—to shrink gland volume over time and reduce long-term risk of disease progression and acute urinary retention. Combination therapy with both drug classes has demonstrated superior efficacy in select populations, particularly those with larger glands and higher baseline PSA.

When medications are ineffective, poorly tolerated, or contraindicated—or when complications arise—minimally invasive procedures such as transurethral resection of the prostate (TURP), laser enucleation (e.g., HoLEP, ThuLEP), or water vapor thermal therapy (Rezūm) offer durable symptom relief and improved urodynamic outcomes. TURP remains the historical gold standard surgical intervention, while modern laser techniques provide comparable efficacy with reduced perioperative bleeding and shorter catheterization times. Emerging options like prostatic urethral lift (PUL) and temporary implantable nitinol devices preserve ejaculatory function and are especially suited for sexually active men prioritizing antegrade ejaculation.

No single “best” treatment exists for all patients. Optimal management requires shared decision-making between clinician and patient—weighing benefits, risks, recovery expectations, and personal priorities—including sexual health, invasiveness, and long-term durability. Regular follow-up and reassessment remain essential, as BPH is a chronic, progressive condition requiring ongoing monitoring and potential therapeutic adjustment over time.